Skip To Main Content
W. Bradford Carter on Muck Rack

W. Bradford Carter

As seen in: ONCOLOGY journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with W. Bradford

Contact W. Bradford, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Sequencing Therapy After ESA Failure in RS-Negative Lower-Risk MDS

|
By W. Bradford Carter, J. Phun, S. Kjelstrom
| ONCOLOGY journal Verified
After a Frontline Forum program, Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discussed how they sequence therapy for patients with ring sideroblast (RS)–negative lower-risk myelodysplastic syndromes (MDS) after failure of an erythropoiesis-stimulating agent (ESA).
Open in Who Shared Issue with article?

Epcoritamab/R2 Earns European Approval for R/R Follicular Lymphoma

|
By W. Bradford Carter, J. Phun, S. Kjelstrom
| ONCOLOGY journal Verified
The European Commission has granted marketing authorization for epcoritamab-bysp (Epkinly; Tepkinly) in combination with lenalidomide (Revlimid) and rituximab (Rituxan; R2) for adult patients with relapsed/refractory follicular lymphoma, according to a news release from the developer, AbbVie.1 The combination is the only bispecific-based therapy approved in Europe for follicular lymphoma in the second-line setting.
Open in Who Shared View Duplicates (2) Issue with article?

FDA Issues Complete Response Letter for Orviglance in Liver Imaging

|
By W. Bradford Carter, J. Phun, S. Kjelstrom
| ONCOLOGY journal Verified
The FDA has issued a complete response letter (CRL) for the new drug application (NDA) of manganese chloride tetrahydrate (Orviglance) for improving the detection and visualization of focal liver lesions on MRI in patients with severely impaired kidney function, according to a news release from the developer, Ascelia Pharma.1 The agency stated it is currently unable to approve the application in its present form and has requested additional clinical data and product documentation.
Open in Who Shared Issue with article?
See all 8 articles